Treatment options for recurrent platinum-sensitive ovarian cancer are evolving.
Most advanced ovarian cancers will recur during or after first-line treatment. Median progression-free survival decreases upon each subsequent recurrence. Patients with ovarian cancer whose disease recurs at least 6 months after treatment completion are considered to be platinum- or chemotherapy-sensitive.
Management options for these patients may include platinum-based combination chemotherapy, secondary cytoreductive surgery, and maintenance therapy. PARP inhibitors and anti-angiogenic agents are also being evaluated as a combination approach.
Explore the module further to learn more about therapies for recurrent platinum-sensitive ovarian cancer—or download the module for later review offline.
Many new treatment options have become available to patients with platinum-sensitive ovarian cancer in recent years, including targeted agents in the maintenance setting. Understanding these options is critical when determining the next course of therapy.